Profile
Adam Houghton is the Chief Business Officer of Upstream Bio, Inc., a clinical-stage biotechnology company focused on inflammatory diseases and the development of verekitug, a receptor antagonist targeting the TSLP pathway. In this role, he leads corporate development, strategic partnerships, and business strategy for the company. The SEC filing context indicates he has held this executive position with Upstream Bio as of the most recent filing date (2026-01-06).
| Role | Insider |
|---|
| Notability | 40/100 |
|---|
Board memberships
Awards & honors
- Led corporate development initiatives for Upstream Bio
- Oversee business strategy and partnerships for the verekitug program targeting the TSLP pathway
Frequently Asked Questions
Who is Houghton Adam?
Adam Houghton is the Chief Business Officer of Upstream Bio, Inc., a clinical-stage biotechnology company focused on inflammatory diseases and the development of verekitug, a receptor antagonist targeting the TSLP pathway. In this role, he leads corporate development, strategic partnerships, and business strategy for the company. The SEC filing context indicates he has held thi…
How many SEC Form 4 filings has Houghton Adam submitted recently?
1 primary Form 4 filings in the last 90 days, covering 1 company.
Has Houghton Adam been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($11K) across all tracked filings.
Where can I see all of Houghton Adam's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.